Elicio Therapeutics Inc (ELTX) Stock Price, Quote & News

Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 209 0050

Website: elicio.com

Address:

451 D Street, 5th Floor Suite 501, Boston, United States

Alt_Fuel Apr. 1 at 11:07 AM

$VSTM $ANL $ELTX $ERAS $RVMD Verastem making Presentations - April 10 to 13, 2026 related to the VSTM collaboration with GenFleet Therapeutics ...

1 · Reply

humdime Apr. 1 at 10:37 AM

Today $ELTX will be presenting at the World Vaccine Congress Washington 2026: “Targeting mKRAS with ELI-002 Cancer Vaccine – Clinical Updates” 12:40 PM Key efficacy data are unlikely to be fully disclosed, but it looks like there could be some new insights or updates shared.

1 · Reply

Alt_Fuel Mar. 31 at 3:15 PM

$VSTM $ELTX $ERAS $RVMD Verastem making Presentations - April 10 to 13, 2026 related to collaboration with GenFleet Therapeutics ...

0 · Reply

Cbra Mar. 30 at 5:49 PM

$ELTX which would be a “positive” from what they are saying, the longer it takes means there’s good data behind the treatment……..so, I’m praying that’s the case!

0 · Reply

Woooehoo Mar. 30 at 3:53 PM

$ELTX we gonna get data in June at this point

0 · Reply

Alt_Fuel Mar. 27 at 9:50 AM

$VSTM April 10 - 13, 2026 ... $ELTX $ERAS $RVMD Verastem is making Presentations at the SGO 2026 Annual Meeting on Women’s Cancer ... Oral Plenary Presentation Details Session: Scientific Plenary I: Advancing Science through Clinical Trials Title: Long-Term Efficacy and Safety of Avutometinib + Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201 Presenter: Rachel Grisham, M.D., Memorial Sloan Kettering Cancer Center - Friday, April 10, 2026, 5:05 pm - 5:13 pm - Poster Presentation Details Session: Poster Title: Exposure-Response Analysis for Avutometinib in Combination with Defactinib in Low-Grade Serous Ovarian Cancer Presenter: Yaofeng Cheng, Ph.D. , Verastem - Sunday, April 12, 2026 Session: Poster Tour Title: Combination targeted and Hormonal treatment of Low-grade serous Ovarian cancer in the upfront setting (CHAMELEON) Presenter: Beryl Manning-Geist, M.D., Emory U. School of Medicine https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-abstracts-accepted-presentation

0 · Reply

Alt_Fuel Mar. 26 at 10:28 AM

$VSTM A comparison of Oncology PIPELINES ... $ELTX - Elicio - https://elicio.com/pipeline/- $ERAS - Erasca - https://www.erasca.com/pipeline/ $RVMD Revolution - https://www.revmed.com/pipeline/ $VSTM Verastem - https://www.verastem.com/research/pipeline/

1 · Reply

Cbra Mar. 23 at 3:40 PM

$ELTX are you concerned they will dilute the price when they release Phase 2 data? They need to raise a lot of money, or partner to complete Phase 3.

1 · Reply

Cbra Mar. 19 at 9:27 PM

$ELTX I was told double that

0 · Reply

Woooehoo Mar. 19 at 7:29 PM

$ELTX what will this need for Phase 3 and other programs? 150M minimum? Ideally partner

0 · Reply

Elicio Therapeutics Reports Inducement Grants

Mar 12, 2026, 4:05 PM EDT - 25 days ago

Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

Feb 25, 2026, 8:00 AM EST - 5 weeks ago

Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Dec 11, 2025, 8:00 AM EST - 4 months ago

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

Nov 19, 2025, 8:00 AM EST - 4 months ago

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

Nov 13, 2025, 4:01 PM EST - 5 months ago

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 7, 2025, 9:00 AM EST - 5 months ago

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

Nov 3, 2025, 8:00 AM EST - 5 months ago

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

Oct 27, 2025, 8:00 AM EDT - 5 months ago

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

Sep 29, 2025, 8:00 AM EDT - 6 months ago

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Sep 17, 2025, 8:00 AM EDT - 7 months ago

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

Aug 12, 2025, 8:00 AM EDT - 8 months ago

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

Aug 7, 2025, 4:30 PM EDT - 8 months ago

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 8 months ago

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

Jun 17, 2025, 8:00 AM EDT - 10 months ago

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

Jun 4, 2025, 8:00 AM EDT - 10 months ago

Elicio Therapeutics Secures $10 Million in Financing

May 13, 2025, 4:05 PM EDT - 11 months ago

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 16, 2025, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Jan 22, 2025, 7:30 AM EST - 1 year ago

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Dec 12, 2024, 7:00 AM EST - 1 year ago

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Sep 13, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Announces Proposed Public Offering

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

May 23, 2024, 5:30 PM EDT - 2 years ago

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

May 15, 2024, 4:30 PM EDT - 2 years ago

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 25, 2024, 8:30 AM EDT - 2 years ago

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 2 years ago

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Mar 29, 2024, 8:30 AM EDT - 2 years ago

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

Mar 6, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Feb 5, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024, 9:00 AM EST - 2 years ago

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Jan 17, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Jan 16, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Jan 9, 2024, 6:00 AM EST - 2 years ago

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Dec 22, 2023, 9:00 AM EST - 2 years ago

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

Dec 4, 2023, 8:00 AM EST - 2 years ago

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 9, 2023, 4:30 PM EST - 2 years ago

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 3, 2023, 4:30 PM EDT - 2 years ago

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC 2023) Annual Meeting

Sep 27, 2023, 5:30 PM EDT - 2 years ago

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

Alt_Fuel Apr. 1 at 11:07 AM

$VSTM $ANL $ELTX $ERAS $RVMD Verastem making Presentations - April 10 to 13, 2026 related to the VSTM collaboration with GenFleet Therapeutics ...

1 · Reply

humdime Apr. 1 at 10:37 AM

1 · Reply

Alt_Fuel Mar. 31 at 3:15 PM

$VSTM $ELTX $ERAS $RVMD Verastem making Presentations - April 10 to 13, 2026 related to collaboration with GenFleet Therapeutics ...

0 · Reply

Cbra Mar. 30 at 5:49 PM

$ELTX which would be a “positive” from what they are saying, the longer it takes means there’s good data behind the treatment……..so, I’m praying that’s the case!

0 · Reply

Woooehoo Mar. 30 at 3:53 PM

$ELTX we gonna get data in June at this point

0 · Reply

Alt_Fuel Mar. 27 at 9:50 AM

0 · Reply

Alt_Fuel Mar. 26 at 10:28 AM

1 · Reply

Cbra Mar. 23 at 3:40 PM

$ELTX are you concerned they will dilute the price when they release Phase 2 data? They need to raise a lot of money, or partner to complete Phase 3.

1 · Reply

Cbra Mar. 19 at 9:27 PM

$ELTX I was told double that

0 · Reply

Woooehoo Mar. 19 at 7:29 PM

$ELTX what will this need for Phase 3 and other programs? 150M minimum? Ideally partner

0 · Reply

humdime Mar. 19 at 7:46 AM

$ELTX At the World Vaccine Congress on April 1st, likely Phase 2 updates — but probably no efficacy data yet.

0 · Reply

PMMstocks Mar. 17 at 8:49 PM

$ELTX

1 · Reply

wetsalmon Mar. 17 at 5:46 PM

$ELTX https://www.aditharun.com/p/can-a-kras-vaccine-change-the-game

1 · Reply

PlayingPossum Mar. 17 at 11:57 AM

$ELTX How many people are in the phase 2 trial?

1 · Reply

Cbra Mar. 17 at 10:06 AM

$ELTX it’s grown 20+% the last month

1 · Reply

PaulNipkow Mar. 17 at 8:01 AM

$ELTX Only 451 followers ? Interesting gem ..

0 · Reply

DARKP00L Mar. 16 at 2:40 PM

$ELTX

0 · Reply

DARKP00L Mar. 16 at 1:43 PM

$ELTX 09:29 on Mar. 16 2026 Elicio Therapeutics Launches $100M At-The-Market Offering Program, Replaces Prior $40M Sales Agreement #tradeideas

0 · Reply

nhyujm6 Mar. 15 at 2:37 AM

$ELTX If you assume ~95/135 patients are MRD-positive (the highest-risk group in resected pancreatic cancer), historical DFS is usually ~6–10 months. With that population mix, you normally wouldn’t expect a long delay in events unless something is slowing recurrence. A rough model with equal MRD distribution across trial and placebo arms suggests a baseline DFS of around ~9–10 months. For the trial timeline to slip like this, the treatment arm would likely need to be meaningfully longer — something like ~15–18 months — implying a hazard ratio of ~0.5–0.6. In pancreatic MRD that would be a VERY strong signal. Many oncology approvals occur around HR ~0.7, so anything near ≤0.6 would be notable and could support a registrational path, buyout/partnering interest, and support an MC trajectory towards 1 Billion.

1 · Reply

WallStreetBuyDip Mar. 13 at 1:29 AM

$ELTX Massive volume spike of 266,700 shares, which is over 3x the average volume of 86,677. Price dropped significantly from $12.90 to $10.90. Smart move to wait for a lower H% before considering entry.

0 · Reply

truehealthvalue Mar. 12 at 9:44 PM

$NVS take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position

0 · Reply

truehealthvalue Mar. 12 at 9:43 PM

$RHHBY take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position

0 · Reply

Market Cap	195.92M
Revenue (ttm)	0.00
Net Income (ttm)	-39.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	5.74

Volume	100,600
Avg Vol	143,708
Day's Range	N/A - N/A
Shares Out	18.40M
Stochastic %K	49%
Beta	1.11
Analysts	Strong Sell
Price Target	$17.33